GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today, Synageva BioPharma Corp's share price is $238.60. Synageva BioPharma Corp's Book Value per Share for the quarter that ended in Mar. 2015 was $19.87. Hence, Synageva BioPharma Corp's P/B Ratio of today is 12.01.
During the past 13 years, Synageva BioPharma Corp's highest P/B Ratio was 17.16. The lowest was 0.76. And the median was 4.27.
During the past 12 months, Synageva BioPharma Corp's average Book Value Per Share Growth Rate was 9.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 49.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Synageva BioPharma Corp was 49.90% per year. The lowest was -43.40% per year. And the median was -3.20% per year.
Synageva BioPharma Corp's P/B ratio for today is calculated as follows:
|P/B Ratio||=||Share Price||/||Book Value per Share (Q: Mar. 2015)|
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book Ratio. The difference between Price-to-Tangible-Book Ratio and Price-to-Book Ratio is that book value other than intangibles are used in the calculation.
Unlike valuation ratios relative to the earning power such as P/E ratio, P/S ratio or Price-to-Free-Cash-Flow ratio, the Price-to-Book Ratio measures the valuation of the stock relative to the underlying asset of the company.
The Price-to-Book Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Synageva BioPharma Corp Annual Data
Synageva BioPharma Corp Quarterly Data